Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Development and Bone Regeneration Capacity of Premixed Magnesium Phosphate Cement Pastes.

Ewald A, Kreczy D, Brückner T, Gbureck U, Bengel M, Hoess A, Nies B, Bator J, Klammert U, Fuchs A.

Materials (Basel). 2019 Jul 1;12(13). pii: E2119. doi: 10.3390/ma12132119.

2.

Prefabricated and Self-Setting Cement Laminates.

Brückner T, Fuchs A, Wistlich L, Hoess A, Nies B, Gbureck U.

Materials (Basel). 2019 Mar 12;12(5). pii: E834. doi: 10.3390/ma12050834.

3.

Unnötige abdominelle Eingriffe bei Patienten mit hereditärem Angioödem.

Hahn J, Hoess A, Friedrich DT, Mayer B, Schauf L, Hoffmann TK, Greve J.

J Dtsch Dermatol Ges. 2018 Dec;16(12):1443-1450. doi: 10.1111/ddg.13698_g. No abstract available.

PMID:
30537315
4.

Unnecessary abdominal interventions in patients with hereditary angioedema.

Hahn J, Hoess A, Friedrich DT, Mayer B, Schauf L, Hoffmann TK, Greve J.

J Dtsch Dermatol Ges. 2018 Dec;16(12):1443-1449. doi: 10.1111/ddg.13698. Epub 2018 Nov 21.

PMID:
30462881
5.

Strontium(II) and mechanical loading additively augment bone formation in calcium phosphate scaffolds.

Reitmaier S, Kovtun A, Schuelke J, Kanter B, Lemm M, Hoess A, Heinemann S, Nies B, Ignatius A.

J Orthop Res. 2018 Jan;36(1):106-117. doi: 10.1002/jor.23623. Epub 2017 Jun 26.

6.

Comparison of a quasi-dynamic and a static extraction method for the cytotoxic evaluation of acrylic bone cements.

Hoess A, López A, Engqvist H, Ott MK, Persson C.

Mater Sci Eng C Mater Biol Appl. 2016 May;62:274-82. doi: 10.1016/j.msec.2016.01.048. Epub 2016 Jan 21.

PMID:
26952424
7.

The effect of oligo(trimethylene carbonate) addition on the stiffness of acrylic bone cement.

Persson C, López A, Fathali H, Hoess A, Rojas R, Ott MK, Hilborn J, Engqvist H.

Biomatter. 2016;6:e1133394. doi: 10.1080/21592535.2015.1133394.

8.

The influence of Sr content in calcium phosphate coatings.

Lindahl C, Pujari-Palmer S, Hoess A, Ott M, Engqvist H, Xia W.

Mater Sci Eng C Mater Biol Appl. 2015 Aug;53:322-30. doi: 10.1016/j.msec.2015.04.015. Epub 2015 Apr 14.

PMID:
26042720
9.

Effects of nanoporous alumina on inflammatory cell response.

Pujari S, Hoess A, Shen J, Thormann A, Heilmann A, Tang L, Karlsson-Ott M.

J Biomed Mater Res A. 2014 Nov;102(11):3773-80. doi: 10.1002/jbm.a.35048. Epub 2013 Dec 9.

10.

Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data.

Combs SE, Kessel KA, Herfarth K, Jensen A, Oertel S, Blattmann C, Ecker S, Hoess A, Martin E, Witt O, Jäkel O, Kulozik AE, Debus J.

Radiat Oncol. 2012 Oct 17;7:170. doi: 10.1186/1748-717X-7-170.

11.

Self-supporting nanoporous alumina membranes as substrates for hepatic cell cultures.

Hoess A, Thormann A, Friedmann A, Heilmann A.

J Biomed Mater Res A. 2012 Sep;100(9):2230-8. doi: 10.1002/jbm.a.34158. Epub 2012 Apr 10.

PMID:
22492687
12.

Role of alumina nanoporosity in acute cell response.

Ferraz N, Hoess A, Thormann A, Heilmann A, Shen J, Tang L, Ott MK.

J Nanosci Nanotechnol. 2011 Aug;11(8):6698-704.

PMID:
22103070
13.

Mesoporous titanium dioxide coating for metallic implants.

Xia W, Grandfield K, Hoess A, Ballo A, Cai Y, Engqvist H.

J Biomed Mater Res B Appl Biomater. 2012 Jan;100(1):82-93. doi: 10.1002/jbm.b.31925. Epub 2011 Sep 27.

PMID:
21954047
14.

Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer - acute toxicity of 12C for PC.

Nikoghosyan AV, Schulz-Ertner D, Herfarth K, Didinger B, Münter MW, Jensen AD, Jäkel O, Hoess A, Haberer T, Debus J.

Acta Oncol. 2011 Aug;50(6):784-90. doi: 10.3109/0284186X.2011.584558.

PMID:
21767175
15.

Investigation of cell-substrate interactions by focused ion beam preparation and scanning electron microscopy.

Friedmann A, Hoess A, Cismak A, Heilmann A.

Acta Biomater. 2011 Jun;7(6):2499-507. doi: 10.1016/j.actbio.2011.02.024. Epub 2011 Feb 21.

PMID:
21345385
16.

Low-modulus PMMA bone cement modified with castor oil.

López A, Hoess A, Thersleff T, Ott M, Engqvist H, Persson C.

Biomed Mater Eng. 2011;21(5-6):323-32. doi: 10.3233/BME-2012-0679.

PMID:
22561251
17.

Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients.

Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jäkel O, Jensen A, Klemm S, Münter M, Naumann J, Nikoghosyan A, Oertel S, Parodi K, Rieken S, Debus J.

Acta Oncol. 2010 Oct;49(7):1132-40. doi: 10.3109/0284186X.2010.498432.

PMID:
20831505
18.

Temporal lobe reactions after radiotherapy with carbon ions: incidence and estimation of the relative biological effectiveness by the local effect model.

Schlampp I, Karger CP, Jäkel O, Scholz M, Didinger B, Nikoghosyan A, Hoess A, Krämer M, Edler L, Debus J, Schulz-Ertner D.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):815-23. doi: 10.1016/j.ijrobp.2010.03.001. Epub 2010 Jul 16.

PMID:
20638186
19.

Time- and dose-dependency of radiographic normal tissue changes of the lung after stereotactic radiotherapy.

Hof H, Zgoda J, Nill S, Hoess A, Kopp-Schneider A, Herfarth K, Debus J, Plathow C.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1369-74. doi: 10.1016/j.ijrobp.2009.06.082. Epub 2009 Nov 24.

PMID:
19932943
20.

Quantitative assessment of image-guided radiotherapy for paraspinal tumors.

Stoiber EM, Lechsel G, Giske K, Muenter MW, Hoess A, Bendl R, Debus J, Huber PE, Thieke C.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):933-40. doi: 10.1016/j.ijrobp.2009.04.010.

PMID:
19596172
21.

Stereotactic single-dose radiotherapy of lung metastases.

Hof H, Hoess A, Oetzel D, Debus J, Herfarth K.

Strahlenther Onkol. 2007 Dec;183(12):673-8.

PMID:
18040611
22.

Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC).

Hof H, Muenter M, Oetzel D, Hoess A, Debus J, Herfarth K.

Cancer. 2007 Jul 1;110(1):148-55.

23.

Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy.

Combs SE, Thilmann C, Huber PE, Hoess A, Debus J, Schulz-Ertner D.

Cancer. 2007 Jun 1;109(11):2308-14.

24.

Cultivation of hepatoma cell line HepG2 on nanoporous aluminum oxide membranes.

Hoess A, Teuscher N, Thormann A, Aurich H, Heilmann A.

Acta Biomater. 2007 Jan;3(1):43-50. Epub 2006 Oct 24.

PMID:
17064971
25.

Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518).

Jensen AD, Münter MW, Bischoff H, Haselmann R, Timke C, Krempien R, Sterzing F, Nill S, Heeger S, Hoess A, Haberkorn U, Huber PE, Steins M, Thomas M, Debus J, Herfarth KK.

BMC Cancer. 2006 May 8;6:122.

26.

Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.

Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, Haberkorn U, Debus J.

Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):222-7. Epub 2006 Feb 20.

PMID:
16488553
27.

Inversely planned intensity modulated radiotherapy of the breast including the internal mammary chain: a plan comparison study.

Thilmann C, Sroka-Perez G, Krempien R, Hoess A, Wannenmacher M, Debus J.

Technol Cancer Res Treat. 2004 Feb;3(1):69-75.

PMID:
14750895
28.

Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC).

Hof H, Herfarth KK, Münter M, Hoess A, Motsch J, Wannenmacher M, Debus J J.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):335-41.

PMID:
12738306
29.

From EST to IHC: human antibody pipeline for target research.

Frisch C, Brocks B, Ostendorp R, Hoess A, von Rüden T, Kretzschmar T.

J Immunol Methods. 2003 Apr 1;275(1-2):203-12.

PMID:
12667684
30.

Results of three-dimensional stereotactically-guided radiotherapy in recurrent medulloblastoma.

Milker-Zabel S, Zabel A, Thilmann C, Zuna I, Hoess A, Wannenmacher M, Debus J.

J Neurooncol. 2002 Dec;60(3):227-33.

PMID:
12510774
31.

Intensity-modulated radiotherapy of the female breast.

Thilmann C, Zabel A, Nill S, Rhein B, Hoess A, Haering P, Milke-Zabel S, Harms W, Schlegel W, Wannenmacher M, Debus J.

Med Dosim. 2002 Summer;27(2):79-90. Review.

PMID:
12074472
32.

Intensity-modulated radiotherapy with an integrated boost to the macroscopic tumor volume in the treatment of high-grade gliomas.

Thilmann C, Zabel A, Grosser KH, Hoess A, Wannenmacher M, Debus J.

Int J Cancer. 2001 Dec 20;96(6):341-9.

33.

High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results.

Debus J, Wuendrich M, Pirzkall A, Hoess A, Schlegel W, Zuna I, Engenhart-Cabillic R, Wannenmacher M.

J Clin Oncol. 2001 Aug 1;19(15):3547-53.

PMID:
11481362
34.

The role of proton therapy in the treatment of large irradiation volumes: a comparative planning study of pancreatic and biliary tumors.

Zurlo A, Lomax A, Hoess A, Bortfeld T, Russo M, Goitein G, Valentini V, Marucci L, Capparella R, Loasses A.

Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):277-88.

PMID:
10924999
35.
36.

Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.

Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wölle J, Plückthun A, Virnekäs B.

J Mol Biol. 2000 Feb 11;296(1):57-86.

PMID:
10656818
37.

Interchangeable endotoxin-binding domains in proteins with opposite lipopolysaccharide-dependent activities.

Schumann RR, Lamping N, Hoess A.

J Immunol. 1997 Dec 1;159(11):5599-605.

PMID:
9548502
38.

Methods for transferring patient and plan data between radiotherapy treatment planning systems.

Bedford JL, Oldham M, Hoess A, Evans PM, Shentall GS, Webb S.

Br J Radiol. 1997 Jul;70(835):740-9.

PMID:
9245886
39.

Effects of site-directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS)-binding protein on binding and transfer of LPS and subsequent immune cell activation.

Lamping N, Hoess A, Yu B, Park TC, Kirschning CJ, Pfeil D, Reuter D, Wright SD, Herrmann F, Schumann RR.

J Immunol. 1996 Nov 15;157(10):4648-56.

PMID:
8906845
40.

High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor.

Ried C, Wahl C, Miethke T, Wellnhofer G, Landgraf C, Schneider-Mergener J, Hoess A.

J Biol Chem. 1996 Nov 8;271(45):28120-7.

41.

Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen.

Rheinnecker M, Hardt C, Ilag LL, Kufer P, Gruber R, Hoess A, Lupas A, Rottenberger C, Plückthun A, Pack P.

J Immunol. 1996 Oct 1;157(7):2989-97.

PMID:
8816407
42.

Identification of the LPS-binding domain of an endotoxin neutralising protein, Limulus anti-LPS factor.

Hoess A, Schneider-Mergener J, Liddington RC.

Prog Clin Biol Res. 1995;392:327-37. No abstract available.

PMID:
8524938
43.

Lipopolysaccharide binding protein: its role and therapeutical potential in inflammation and sepsis.

Schumann RR, Lamping N, Kirschning C, Knopf HP, Hoess A, Herrmann F.

Biochem Soc Trans. 1994 Feb;22(1):80-2. Review. No abstract available.

PMID:
7515836
44.

Supplemental Content

Support Center